Navigation Links
Cervarix Proves Effective Against HPV for Over 6 Years
Date:12/3/2009

Vaccine protected volunteers from virus linked to cervical cancer

WEDNESDAY, Dec. 2 (HealthDay News) -- The human papillomavirus (HPV) vaccine Cervarix protects women from infection for longer than six years, new research has found.

The vaccine guards against the two types of HPV (HPV-16 and HPV-18) most commonly associated with cervical cancer.

The study looked at nearly 800 women, aged 15 to 25, with a normal cervical profile and no evidence of HPV infection at the start of the trial. There were 393 women who received the Cervarix vaccine and 383 who received an inactive placebo. Every six months for 6.4 years, the women were tested for HPV DNA.

The researchers found that vaccine efficacy against 12-month persistent infection with HPV-16/18 remained 100 percent during the study period. Vaccine efficacy against incident infection with HPV-16/18 was 95 percent. Antibody concentrations against HPV-16/18 in vaccinated women remained at least several-fold higher than would be found after natural HPV infection, the study authors noted.

Cervarix also protected women against incident infection with HPV-31 and HPV-45, which "are among the types most frequently associated with cervical cancer after HPV-16 and HPV-18, and are responsible for 10 percent of all cervical cancer cases," wrote Dr. Cosette Wheeler, of the Health Sciences Center at the University of New Mexico, and colleagues.

The study was released online Dec. 2 in advance of publication in an upcoming print issue of The Lancet.

"Although further assessment is necessary to confirm long-term vaccine effects, in view of the data from our study, we expect protection to continue for many more years," the researchers concluded.

Cervarix, from GlaxoSmithKline, received U.S. Food and Drug Administration approval in October.

More information

The U.S. National Cancer Institute has more about HPV vaccines.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Japanese Zen ... Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on ... mat art pieces, such as Zen Kodo mat. Wanderlust , one of the ...
(Date:9/21/2017)... Boulder, CO (PRWEB) , ... September 21, 2017 ... ... Education Interview of the Month, Lewis and Clark College Emeritus Professor of Education ... Associate Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... voice for people who have kidney disease. The theme “Describe a positive decision ... stories. Entrants needed to meet only one qualification— to have been diagnosed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced ... Aligner clinical and commercial support services market) has entered into an agreement on ... Australia. , The PGSD is the first private Dental School to launch ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot ... Vaginas.” The goal is to ignite conversation via social media and word-of-mouth regarding ... brand has declared September “Humans with Vaginas” month, releasing a video celebrating the ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: